Form 4: Sutro Biopharma CFO Acquires Shares

Sutro Biopharma CFO Gregory K. Chow acquired 2,500 shares of common stock and 2,500 Restricted Stock Units (RSUs) on June 2, 2026.

Summary

• Gregory K. Chow, CFO of Sutro Biopharma, Inc., reported a transaction on June 2, 2026.
• Chow acquired 2,500 shares of common stock.
• Additionally, Chow was granted 2,500 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock.
• The RSUs vest annually, with the first tranche vesting on June 2, 2026.
• Chow elected to satisfy tax withholding liabilities in cash in lieu of withholding shares.
• The total number of common shares beneficially owned by Chow following these transactions is 4,725.
• Chow also beneficially owns 7,500 shares through RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a routine insider transaction related to executive compensation and does not provide new financial performance data or strategic insights.

Positives

• The CFO's acquisition of shares and RSUs may indicate confidence in the company's future prospects.
• The vesting of the first tranche of RSUs on June 2, 2026, signifies progress in the executive's equity compensation plan.
• The acquisition of 250 shares through the employee stock purchase plan, exempt under Rule 16b-3(c), suggests ongoing participation in company equity programs.

Negatives

• The filing does not contain information that would be considered negative.

Risks

• The value of the acquired shares and RSUs is subject to market fluctuations and the company's performance.
• The vesting of RSUs is contingent upon continued service to the Issuer.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future financial performance. However, the acquisition of stock and RSUs by the CFO may imply a positive outlook from management.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by the CFO of Sutro Biopharma, are common in the biotechnology sector. These filings provide transparency into executive compensation and potential insider confidence, though they do not directly reflect company performance or strategic shifts.

Stakeholder Impact

• Shareholders: The transaction provides transparency into executive compensation and potential insider confidence, but does not directly impact current share value.
• Employees: The filing relates to executive compensation and does not directly affect other employees.
• Management: The transaction is part of the CFO's compensation package and reflects ongoing engagement with the company.

Next Steps

• Continued vesting of RSUs annually through June 2, 2029, subject to continued service.
• Potential future transactions by the reporting person, which will be reported on subsequent Form 4 filings.

Key Dates

Keywords

Sutro Biopharma, STRO, Form 4, Insider Trading, Stock Acquisition, Restricted Stock Units, RSU, CFO, Gregory K. Chow, Beneficial Ownership, Securities Exchange Act